Ad is loading...
MLYS
Price
$12.45
Change
+$0.58 (+4.89%)
Updated
Nov 22, 03:30 PM (EDT)
PRME
Price
$3.29
Change
+$0.32 (+10.77%)
Updated
Nov 22, 03:34 PM (EDT)
Ad is loading...

MLYS vs PRME

Header iconMLYS vs PRME Comparison
Open Charts MLYS vs PRMEBanner chart's image
Mineralys Therapeutics
Price$12.45
Change+$0.58 (+4.89%)
Volume$300
CapitalizationN/A
Prime Medicine
Price$3.29
Change+$0.32 (+10.77%)
Volume$1.89K
CapitalizationN/A
MLYS vs PRME Comparison Chart
Loading...
MLYS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
MLYS vs. PRME commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLYS is a Sell and PRME is a Buy.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (MLYS: $11.87 vs. PRME: $2.97)
Brand notoriety: MLYS and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLYS: 128% vs. PRME: 53%
Market capitalization -- MLYS: $590.75M vs. PRME: $389.55M
MLYS [@Biotechnology] is valued at $590.75M. PRME’s [@Biotechnology] market capitalization is $389.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLYS’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • MLYS’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, MLYS is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLYS’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).

  • MLYS’s TA Score: 5 bullish, 6 bearish.
  • PRME’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both MLYS and PRME are a bad buy in the short-term.

Price Growth

MLYS (@Biotechnology) experienced а -2.47% price change this week, while PRME (@Biotechnology) price change was -17.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +4.04%.

Reported Earning Dates

MLYS is expected to report earnings on Nov 11, 2024.

PRME is expected to report earnings on Nov 13, 2024.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MLYS($591M) has a higher market cap than PRME($390M). MLYS YTD gains are higher at: 38.023 vs. PRME (-66.479). MLYS has higher annual earnings (EBITDA): -168.35M vs. PRME (-207.13M). MLYS has more cash in the bank: 264M vs. PRME (176M). PRME has higher revenues than MLYS: PRME (800K) vs MLYS (0).
MLYSPRMEMLYS / PRME
Capitalization591M390M152%
EBITDA-168.35M-207.13M81%
Gain YTD38.023-66.479-57%
P/E RatioN/AN/A-
Revenue0800K-
Total Cash264M176M150%
Total DebtN/A41.2M-
FUNDAMENTALS RATINGS
PRME: Fundamental Ratings
PRME
OUTLOOK RATING
1..100
55
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
93
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MLYSPRME
RSI
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 17 days ago
89%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
MLYS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DMCFX31.890.55
+1.75%
Invesco Discovery Mid Cap Growth R5
RYIAX121.921.53
+1.27%
Rydex Internet H
GPROX16.270.08
+0.49%
Grandeur Peak Global Reach Inv
RMGSX10.880.01
+0.09%
Russell Inv Multi-Asset Growth Strat S
MXHAX13.70N/A
N/A
Empower Large Cap Value Inv II

MLYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with RXRX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLYS
1D Price
Change %
MLYS100%
-5.79%
RXRX - MLYS
40%
Loosely correlated
-4.80%
ADCT - MLYS
40%
Loosely correlated
-2.02%
PLRX - MLYS
40%
Loosely correlated
+0.94%
PRME - MLYS
40%
Loosely correlated
-0.67%
LYEL - MLYS
39%
Loosely correlated
-11.01%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-0.67%
BEAM - PRME
61%
Loosely correlated
-3.72%
NTLA - PRME
61%
Loosely correlated
+5.18%
CRSP - PRME
60%
Loosely correlated
-2.05%
ABCL - PRME
57%
Loosely correlated
+1.87%
RXRX - PRME
55%
Loosely correlated
-4.80%
More